Biosenta's Tri-Filler™ Antimicrobial Nanotechnology Validated by University of Calgary with Over 200x Enhanced Antibacterial Performance

University of Calgary Study Confirms Tri-Filler's Superior Antimicrobial Performance Over Calcium Hydroxide

On 21 July 2026, the University of Calgary published laboratory testing results demonstrating Biosenta's Tri-Filler™ technology significantly outperforms calcium hydroxide, a common antimicrobial agent in commercial use. The study revealed Tri-Filler delivers more than a 200-fold enhancement in antibacterial activity, indicating a breakthrough in antimicrobial material effectiveness applicable across multiple industries.

The research was conducted by Dr. Maen Husein from the Schulich School of Engineering and Dr. Mehdi Mohammadi Ashani of the Department of Biological Sciences, with support from Dr. Reza Lashkari and Dr. Noora Darwish. This collaborative effort between the University of Calgary, Biosenta, and the Alberta Centre for Advanced Diagnostics (ACAD) provided independent, peer-reviewed validation of Tri-Filler's laboratory performance.

Durability Testing Demonstrates Tri-Filler's Long-Term Stability in Harsh Conditions

Beyond immediate antimicrobial effectiveness, the University of Calgary assessed Tri-Filler's durability under elevated temperature and humidity for over one year. The material maintained both its structural integrity and antibacterial properties, simulating real-world industrial and institutional environments.

This long-term stability is critical for commercial use, as it reduces the need for frequent replacements and maintenance. For Biosenta, these durability results enhance the appeal of Tri-Filler for customers seeking lasting antimicrobial protection in coatings, paints, concrete, and other materials used in high-contact areas where contamination control is vital.

Innovative Tri-Filler Technology Designed for Embedded Antimicrobial Protection in Building Materials

Tri-Filler is a proprietary core-shell antimicrobial nanotechnology engineered to be integrated into coatings, paints, concrete, and other building materials for high-contact environments. Its controlled-release mechanism ensures sustained antimicrobial activity embedded within the material, eliminating reliance on surface treatments or external applications. This embedded approach offers operational benefits where reapplication is impractical or costly.

The University of Calgary highlighted potential commercial applications including hospitals, schools, daycares, public transportation, and other institutional or public venues where microbial contamination reduction is critical. These sectors face regulatory requirements and infection control mandates, creating demand for validated long-lasting antimicrobial building materials.

Ongoing Multi-Year Collaboration Between Biosenta and University of Calgary

Biosenta has partnered with the University of Calgary's scientific team over several years to advance Tri-Filler from laboratory development toward commercial readiness. This sustained collaboration reflects the iterative nature of antimicrobial innovation, requiring extensive research investment and cross-institutional expertise.

Dr. Mehdi Mohammadi Ashani, Senior Scientist at Biosenta and University of Calgary Biological Sciences faculty member, emphasized the partnership's focus on evaluating Tri-Filler beyond initial lab tests. Their work includes performance metrics and data generation essential for product development and regulatory submissions.

CEO Highlights Importance of Independent Validation and Upcoming Development Stages

Am Gill, President and CEO of Biosenta, described the University of Calgary’s independent validation as a key milestone for the Tri-Filler program. He stated that endorsement from a leading Canadian research institution strengthens the scientific foundation and supports Biosenta’s commercialization goals.

Gill confirmed that Biosenta will continue collaboration with research partners during product validation, regulatory filings, and commercialization phases, aligning with standard antimicrobial material development processes where independent validation complements regulatory and market entry activities.

Field Testing Initiative to Provide Real-World Performance Insights

Biosenta and its partners plan field testing to gather structured observations and quantitative data, informing further product development, strategic partnerships, and market adoption. Field trials will assess performance under actual use conditions, including installation methods, environmental factors, user practices, and durability metrics not replicable in labs.

Data from field testing will support regulatory submissions, manufacturing scale-up decisions, and customer evaluations, bridging the gap between laboratory validation and commercial deployment.

Biosenta’s Commercialization Strategy Encompasses Validation, Scale-Up, Regulatory, and Partnerships

Biosenta’s commercialization roadmap includes ongoing product validation, manufacturing scale-up, regulatory engagement, and strategic partnerships aimed at market introduction. Scaling manufacturing ensures Tri-Filler can be produced at commercial volumes while maintaining performance consistency demonstrated in labs.

Regulatory activities will address building material standards, antimicrobial efficacy claims, and sector-specific requirements such as healthcare. Strategic collaborations with coatings, paints, concrete, and construction industry players aim to accelerate market penetration leveraging existing distribution and customer networks.

Company Profile: Biosenta’s Environmentally Friendly Antimicrobial Solutions

Based in Toronto, Ontario, and Calgary, Alberta, Biosenta develops antimicrobial products positioned as eco-friendly alternatives to traditional solutions. Its proprietary nanoparticle technology offers durable protection against a broad spectrum of bacteria, molds, and fungi.

Environmental sustainability is a key differentiator, especially in institutional procurement and regulated sectors. Healthcare, education, and transportation industries increasingly prioritize antimicrobial solutions that combine efficacy, safety, environmental impact, and durability—criteria met by Biosenta’s independently validated, laboratory-tested materials.

Regulatory Landscape and Market Adoption for Antimicrobial Building Materials

Antimicrobial building materials face regulatory frameworks involving multiple standards and testing protocols. Depending on application—healthcare, food-contact, or general construction—Biosenta must navigate product standards, efficacy claim regulations, safety assessments, and sector-specific certifications. The independent University of Calgary validation provides foundational evidence supporting regulatory submissions and customer qualification.

Market adoption typically involves evaluation periods, comparative testing, and integration into procurement standards. Tri-Filler’s independent validation and durability data position it as a differentiated offering versus conventional antimicrobial compounds. Biosenta’s emphasis on strategic partnerships reflects recognition that collaboration with established manufacturers and distributors is essential for successful market entry rather than direct-to-consumer approaches.